Litigation Details for NOVARTIS AG v. KAPPOS (D.D.C. 2010)

« Back to Dashboard

NOVARTIS AG v. KAPPOS (D.D.C. 2010)

Docket	1:10-cv-01138	Date Filed	2010-07-06
Court	District Court, District of Columbia	Date Terminated	2012-11-15
Cause	35:145 Patent Infringement	Assigned To	Ellen Segal Huvelle
Jury Demand	None	Referred To
Parties	DANA-FARBER CANCER INSTITUTE; NOVARTIS CORPORATION
Patents	6,878,721; 7,973,031
Attorneys	Benjamin D.M. Wood; Mitchell P. Zeff
Firms	U.S. ATTORNEY'S OFFICE FOR THE DISTRICT OF COLUMBIA, Criminal Division Felony Major Crimes
Link to Docket	External link to docket

Details for NOVARTIS AG v. KAPPOS (D.D.C. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-07-06				External link to document

Litigation summary and analysis for: NOVARTIS AG v. KAPPOS (D.D.C. 2010)

Last updated: August 8, 2026

Novartis AG v. Kappos, No. 1:10-cv-01138 (D.D.C.), was a patent-term-adjustment dispute under the Administrative Procedure Act, not a Hatch-Waxman infringement case. Novartis challenged the USPTO’s methodology for calculating patent term adjustment, particularly the treatment of examination delays after a request for continued examination and the statutory overlap between different categories of USPTO delay. The litigation led to the Federal Circuit’s decision in Novartis AG v. Lee, 740 F.3d 1349 (Fed. Cir. 2014), which required the USPTO to revise part of its calculation methodology.

Novartis AG v. Kappos, No. 1:10-cv-01138: Litigation Summary and Patent-Term Analysis

What was Novartis AG v. Kappos about?

The case concerned the calculation of patent term adjustment, or PTA, under 35 U.S.C. § 154(b). PTA extends a patent’s 20-year term to compensate for specified delays attributable to the USPTO.

Novartis argued that the USPTO had improperly reduced the PTA available for two Novartis patents by:

• Excluding certain post-request-for-continued-examination, or RCE, periods from the three-year examination guarantee under § 154(b)(1)(B).
• Applying an overly broad interpretation of “overlap” under § 154(b)(2)(A).
• Failing to award the full term adjustment required by the statute.

The action was brought against USPTO Director David Kappos under the APA. The district-court docket was No. 1:10-cv-01138 in the U.S. District Court for the District of Columbia.

Item	Detail
Plaintiff	Novartis AG
Defendant	David Kappos, Director of the USPTO
Court	U.S. District Court for the District of Columbia
District-court docket	No. 1:10-cv-01138
Federal Circuit caption	Novartis AG v. Lee
Core statute	35 U.S.C. § 154(b)
Case type	APA challenge to USPTO patent-term-adjustment calculation
Hatch-Waxman infringement claim	None
Paragraph IV challenge	None
FDA action	None
Main legal issue	Calculation of USPTO-delay patent term adjustment

What patents and patent terms were at issue?

The district-court litigation challenged PTA calculations for two Novartis patents. The dispute was directed at the USPTO’s term calculations rather than the validity, enforceability, infringement, or scope of the patents’ claims.

The case is therefore different from a conventional pharmaceutical patent lawsuit. The court did not decide whether a generic product infringed a drug patent. It decided how much additional patent term Novartis should receive for USPTO delay.

The case record and appellate decision identify the patents as pharmaceutical patents owned by Novartis, but the controlling legal issue was methodological. The Federal Circuit’s decision applied broadly to patent applicants and patentees whose PTA calculations included an RCE or extended prosecution period.

When does patent term adjustment apply under 35 U.S.C. § 154(b)?

Section 154(b) provides three primary categories of PTA:

PTA category	Statutory provision	General description
A delay	§ 154(b)(1)(A)	USPTO failure to meet specified examination and response deadlines
B delay	§ 154(b)(1)(B)	Application remains pending more than three years, subject to statutory exclusions
C delay	§ 154(b)(1)(C)	Delay caused by appellate review, secrecy orders, or interference proceedings
Applicant delay reduction	§ 154(b)(2)(C)	Reduction for applicant-caused delays
Overlap reduction	§ 154(b)(2)(A)	Reduction where delay periods overlap

The Novartis litigation primarily concerned B delay and the interaction between B delay, A delay, and applicant actions such as filing an RCE.

What is B-delay patent term adjustment?

B delay compensates an applicant when the USPTO does not issue a patent within three years after the actual filing date. The statute excludes several periods from the three-year calculation, including certain applicant-requested examination periods.

The USPTO historically treated the filing of an RCE as creating a broad exclusion from B-delay accrual. Novartis challenged that approach when the application remained pending beyond the three-year statutory period.

What did the district court decide?

The district court reviewed the USPTO’s calculation under the APA. In Novartis AG v. Kappos, 904 F. Supp. 2d 58 (D.D.C. 2012), the court addressed whether the USPTO’s interpretation of § 154(b) was consistent with the statute.

The district court generally upheld the USPTO’s methodology, including its approach to overlap and the treatment of RCE-related periods. The court’s reasoning accepted substantial portions of the agency’s interpretation of the PTA statute.

Novartis appealed to the U.S. Court of Appeals for the Federal Circuit.

What did the Federal Circuit decide in Novartis AG v. Lee?

The Federal Circuit issued its decision on January 15, 2014. The caption changed from Kappos to Lee after Michelle K. Lee became USPTO Director.

The Federal Circuit held that the USPTO’s blanket exclusion of time after an RCE from B-delay calculations was inconsistent with the statutory text. The court held that post-RCE time could qualify for B-delay when the application had remained pending for more than three years, subject to statutory exclusions and applicant-delay deductions.

The Federal Circuit’s main conclusions were:

1. The USPTO could not categorically exclude all time after an RCE from B-delay.
2. The relevant question was whether the application remained pending more than three years after its actual filing date.
3. Time before the three-year date generally could not generate B delay because the statutory three-year threshold had not yet been reached.
4. Time after the three-year date could qualify for B delay even if an RCE had been filed, unless another statutory exclusion applied.
5. Applicant-caused delay still had to be deducted.
6. The USPTO’s overlap methodology was largely sustained.

The court remanded for recalculation of the affected PTA periods.

What was the Federal Circuit citation?

The appellate decision is:

Novartis AG v. Lee, 740 F.3d 1349 (Fed. Cir. 2014).

The decision is often cited as a leading authority on RCE-related PTA and the calculation of B delay.

How did Novartis AG v. Lee change patent-term calculations?

Before the decision, the USPTO’s position treated an RCE as cutting off B-delay accrual. Under that approach, a patent applicant could lose PTA for the period after an application crossed the three-year threshold if the applicant had filed an RCE.

The Federal Circuit rejected that categorical rule. The operative framework became:

1. Determine the application’s total pendency.
2. Identify when the three-year period expired.
3. Calculate B delay for qualifying time after that date.
4. Exclude statutory periods that do not count.
5. Deduct applicant delay.
6. Apply the statutory overlap provision.

This change was commercially relevant for long-pending pharmaceutical applications. Pharmaceutical patent prosecution frequently involves:

• Multiple office actions.
• Continuation practice.
• RCE filings.
• Claim amendments.
• Examiner interviews.
• Patentability disputes involving complex chemistry or biology.

A longer PTA period can extend the enforceable life of a pharmaceutical patent beyond the nominal 20-year term measured from the earliest effective nonprovisional filing date.

What was the litigation outcome?

The Federal Circuit affirmed in part, vacated or reversed in part, and remanded for further proceedings consistent with its interpretation of § 154(b).

Stage	Result
USPTO	Calculated PTA using its existing methodology
D.D.C.	Generally upheld the USPTO’s interpretation
Federal Circuit	Rejected the categorical exclusion of post-RCE B delay
Final procedural disposition	Remand for recalculation

The appellate decision did not invalidate Novartis’s patents. It did not determine infringement. It did not order a generic launch or prohibit a competing product. The principal remedy was recalculation of patent term adjustment.

Did the case involve Paragraph IV litigation or generic entry?

No. Novartis AG v. Kappos was not a Paragraph IV case and did not involve an Abbreviated New Drug Application, an ANDA filer, a 30-month stay, or a generic launch schedule.

The dispute affected potential exclusivity duration indirectly. A successful PTA challenge could extend the enforceable term of a patent, which could delay generic entry if the patent covered an FDA-approved product and remained listed or otherwise enforceable. The case itself, however, did not decide whether any generic product infringed or whether any product could enter the market.

What was the FDA and Orange Book status?

The litigation did not involve an FDA approval decision or an Orange Book listing dispute.

Regulatory issue	Status in this case
NDA approval	Not adjudicated
ANDA filing	Not adjudicated
Paragraph IV certification	None
Orange Book listing	Not the subject of the case
30-month stay	None
Patent-use code dispute	None
FDA exclusivity	Not adjudicated
Biosimilar application	None

The case should not be used as authority for Orange Book listing requirements, patent-use codes, pediatric exclusivity, new chemical entity exclusivity, or biologic patent litigation.

How strong was Novartis’s patent position after the ruling?

The ruling improved Novartis’s potential patent-term position for the affected patents by requiring the USPTO to reconsider PTA that had been excluded under the agency’s RCE rule. It did not strengthen the substantive validity of the patent claims.

Patent strength has at least four separate dimensions:

Dimension	Effect of the case
Patent term	Potentially increased through PTA recalculation
Claim validity	Not decided
Infringement position	Not decided
Enforceability	Not decided
FDA exclusivity	Not decided
Generic-entry timing	Potentially affected indirectly

The decision was strongest as a term-extension precedent. It was not a ruling on claim construction, obviousness, written description, enablement, inequitable conduct, or patent eligibility.

What manufacturing and formulation barriers were involved?

No manufacturing-process or formulation patent dispute was litigated in this action. The case did not address:

• Solid-state forms.
• Polymorphs.
• Salts.
• Crystalline intermediates.
• Drug-delivery systems.
• Dosing regimens.
• Manufacturing controls.
• Process patents.
• Formulation patents.
• Method-of-use claims.

Its relevance to formulation and manufacturing estates is indirect. If a formulation or process patent had a PTA-eligible prosecution history, the Federal Circuit’s methodology could affect the patent’s expiration date. The decision did not establish that such patents were valid or enforceable.

How does this case compare with conventional pharmaceutical patent litigation?

Issue	Novartis AG v. Kappos	Hatch-Waxman patent case
Defendant	USPTO Director	Generic drug applicant
Legal framework	APA and patent-term statute	Patent infringement under § 271(e)(2)
Main issue	PTA calculation	Validity, infringement, or enforceability
FDA proceeding	None	ANDA or NDA-related
Paragraph IV	None	Usually central
Injunction risk	None in the conventional sense	Potential generic-launch injunction
Remedy	PTA recalculation	Injunction, judgment, settlement, or launch
Commercial impact	Patent-term timing	Product-specific market entry

This distinction matters for diligence. A citation to Novartis AG v. Kappos supports a patent-term analysis. It does not establish that a Novartis drug patent blocks a generic, survives invalidity review, or qualifies for Orange Book enforcement.

Which companies were challenging Novartis’s patents?

No generic company was a party to the case. The named defendant was the USPTO Director, and the dispute was between Novartis and the federal agency over patent-term calculation.

There was no ANDA challenger, biosimilar applicant, co-defendant, licensing partner, or settlement agreement in the reported litigation.

Did the parties enter a settlement agreement?

No reported settlement agreement resolved the central legal issue. The Federal Circuit issued a merits decision and remanded the matter for recalculation.

The case therefore has precedential value rather than settlement-value significance. Its importance lies in the interpretation of § 154(b), especially the treatment of post-RCE periods.

What is the commercial significance for pharmaceutical companies?

The decision affected the value of long-prosecuted pharmaceutical patent applications. A PTA increase can influence:

• Remaining patent life at product launch.
• The length of the period before generic competition.
• Licensing valuations.
• Forecasted branded revenue.
• Patent-expiration analyses.
• Product-specific loss-of-exclusivity models.
• Continuation and RCE prosecution strategy.

The financial impact depends on the product covered by the patent, the patent’s claim scope, other blocking patents, regulatory exclusivity, and the probability that a generic challenger would prevail. The case itself did not quantify revenue exposure.

For portfolio management, the decision supports a more granular audit of:

• The actual filing date.
• RCE filing dates.
• Three-year pendency thresholds.
• USPTO delay periods.
• Applicant-delay periods.
• PTA certificates.
• Continuation and divisional relationships.
• Patent expiration dates used in commercial forecasts.

What is the current legal significance of Novartis AG v. Kappos?

Novartis AG v. Lee remains a leading Federal Circuit decision on PTA calculation. Its principal rule is that an RCE does not automatically eliminate all subsequent B delay. The USPTO must calculate PTA based on the statutory framework rather than apply a categorical post-RCE exclusion.

The decision is most relevant to:

• Patent-term audits.
• PTA correction requests.
• Pharmaceutical patent expiration analysis.
• Prosecution strategy.
• Patent portfolio valuation.
• Litigation involving the correct expiration date.

It is less relevant to substantive patent validity, Orange Book disputes, generic infringement, biosimilar litigation, or FDA exclusivity.

Key Takeaways

• Novartis AG v. Kappos, No. 1:10-cv-01138, was an APA challenge to USPTO patent-term-adjustment calculations.
• The case did not involve a generic manufacturer, Paragraph IV certification, Orange Book listing, FDA approval, or biosimilar litigation.
• The Federal Circuit’s controlling decision is Novartis AG v. Lee, 740 F.3d 1349 (Fed. Cir. 2014).
• The Federal Circuit rejected the USPTO’s categorical exclusion of post-RCE periods from B-delay calculations.
• Qualifying time after the three-year pendency threshold can generate B delay, subject to statutory exclusions and applicant-delay deductions.
• The ruling potentially extended the term of Novartis patents but did not decide validity, infringement, or enforceability.
• The commercial effect is product-specific and depends on whether the affected patents materially constrain generic or competing entry.

FAQs

Can Novartis AG v. Lee extend a drug patent beyond its listed expiration date?

It can require a revised PTA calculation that produces a later expiration date. The actual extension depends on the patent’s prosecution history and the USPTO’s recalculation.

Does filing an RCE eliminate patent term adjustment?

No. Filing an RCE may exclude certain periods, but it does not automatically eliminate all B-delay accrual after the three-year pendency threshold.

Does the ruling apply to continuation and divisional applications?

The statutory calculation applies to qualifying patent applications, but each application requires a separate prosecution-history analysis. Continuation and divisional relationships can materially affect the relevant filing date and PTA calculation.

Can a patent owner challenge the USPTO’s PTA certificate after issuance?

Yes. Section 154(b)(4) provides a judicial-review mechanism for PTA disputes, subject to statutory timing requirements. Novartis’s action is an example of judicial review of the agency’s calculation methodology.

Does a PTA increase create new FDA exclusivity?

No. PTA extends the patent term. It does not create new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or biologic exclusivity.

References

1. Novartis AG v. Kappos, 904 F. Supp. 2d 58 (D.D.C. 2012).

2. Novartis AG v. Lee, 740 F.3d 1349 (Fed. Cir. 2014).

3. Patent Act, 35 U.S.C. § 154(b) (2024).

4. U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure § 2730: Patent term adjustment under 35 U.S.C. § 154(b). https://www.uspto.gov/web/offices/pac/mpep/s2730.html